The world’s most documented Bifidobacterium reviewed in new scientific paper

A scientific review on Chr. Hansen’s probiotic strain bifidobacterium, BB-12® has just been published in the peer-reviewed scientific journal "Microorganisms"

The review entitled "The Science behind the Probiotic Strain Bifidobacterium animalis subsp. lactis BB-12^®" provides a comprehensive insight into the characteristics and health benefits of the BB-12^® probiotic strain. The paper encompasses key data on the BB-12^® probiotic strain ― from taxonomy, strain characteristics and mechanisms, to clinical efficacy ― and it concludes that “BB-12^® has well-established probiotic characteristics and proven beneficial health effects within gastrointestinal health and immune function.”

In terms of immune function, clinical studies have shown that the BB-12^® probiotic strain increases the body’s resistance to common respiratory infections by interacting with the immune system. Furthermore, survival of the BB-12^® probiotic strain through the gastrointestinal tract has been demonstrated and the BB-12^® probiotic strain has been shown to support a healthy gastrointestinal microbiota.

The world’s most documented probiotic Bifidobacterium
“The BB-12^® probiotic strain has been described in numerous scientific publications out of which more than 130 are publications of human clinical studies covering a variety of consumer groups from newborn preterm infants to elderly across various health areas. More than 200 publications are available via the Medline/PubMed publication database.

Other main probiotic bifidobacteria strains have less than 50 publications on the database. This makes Bifidobacterium animalis subsp. lactis (BB-12^®) the world’s best documented probiotic Bifidobacterium,” explains Mikkel Jungersen MSc, Scientific Advisor, Scientific Affairs, Human Health & Nutrition.

All information in one document

“We expect our customers to warmly welcome the fact that all relevant information about the BB-12^® probiotic strain is now compiled in one document”, says Lasse Nagell, Vice President, Global Sales & Marketing, Human Health & Nutrition.

“A lot of information is available on probiotics today. However the information varies a lot from strain to strain and from supplier to supplier so the reader may be left with a very fragmented picture. The review of the BB-12^® probiotic strain is a valuable tool communicating clear facts and data about this specific strain,” Lasse Nagell concludes.

The review was published in Microorganisms (2014, 2(2), 92-110) in a Special Issue "Advances and New Perspectives in Microbial Research". The paper is open-access and can be read here: http://www.mdpi.com/2076-2607/2/2/92

Photo:

The review, which is authored by Chr. Hansen scientists, finds that beneficial health effects of the BB-12® probiotic strain have been demonstrated through extensive clinical research. The BB-12® probiotic strain has been shown to improve bowel function, to have a protective effect against diarrhea, and to reduce side effects of antibiotic treatment.

Bifidobacterium, BB-12^®: safety and origin

• Originates from Chr. Hansen’s collection of dairy cultures
• Identified as Bifidobacterium animalis subsp. lactis
• Used worldwide since 1985 with no reported adverse events
• Tested in clinical studies with no reported adverse events
• GRAS (Generally Recognized As Safe) notified by FDA
• QPS (Qualified Presumption of Safety) granted by EFSA

BB12^® is a registered trademark of Chr. Hansen A/S.